Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

80.0%

4 terminated/withdrawn out of 5 trials

Success Rate

20.0%

-66.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01681433Phase 2Terminated

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Role: lead

NCT02677727Completed

Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor

Role: lead

NCT03960151Phase 2Withdrawn

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Role: lead

NCT02492360Withdrawn

Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy

Role: lead

NCT02078089Phase 1Terminated

Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Role: lead

All 5 trials loaded